Global Acute Lung Injury Market to Reach $3.09 Billion by 2029, Growing at 4% CAGR

What Is the Expected Size and Growth Rate of the Acute Lung Injury Market?
The market size for acute lung injury has seen consistent growth in recent years. It is projected to escalate from $2.48 billion in 2024 to $2.60 billion in 2025, with a compound annual growth rate (CAGR) of 4.7%. The expansion in the previous period is due to increased awareness campaigns, growth in ICU admission rates, the impacts of smoking and air pollution, hospital-based infections, and initiatives to decrease the mortality rate.

There is an anticipation for a consistent growth in the acute lung injury market size in the coming years. It is projected to rise to $3.09 billion in 2029 with a compound annual growth rate (CAGR) of 4.4%. This growth during the projected period could be due to aspects such as biologics and gene therapies, government budget allocations and aid, the advancement in precision medicine, regeneration medicine and stem cell treatments, coupled with reforms in the worldwide health policy. The forecast period further shows primary trends such as progression in biologic drugs, wearable and long-distance monitoring devices, therapies relying on inhalation, technologies based on CRISPR and gene editing, and biosensors that allow real-time analysis.

What Factors Are Fueling Growth in the Acute Lung Injury Market?
The growing incidence of respiratory conditions is predicted to accelerate the expansion of the acute lung injury market in the future. Conditions affecting the lungs and other components of the respiratory system, which can lead to breathing difficulties and compromised lung function, are grouped as respiratory diseases. Factors like increased air pollution, smoking habits, sedentary lifestyles, aging demographics and the effects of viral infections can be attributed to the escalation of these diseases. Diseases such as pneumonia trigger acute lung injury by causing serious inflammation and damage to the alveoli, which results in compromised gas exchange and respiratory distress. For instance, the Australian Bureau of Statistics reported in September 2023 that the death rate from influenza and pneumonia in the country had escalated from 31.9 per 100,000 people in 2021 to 42.6 per 100,000 people in 2022, showing an approximate surge of 33.54%. As a result, the growing incidence of respiratory diseases is fueling the expansion of the acute lung injury market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20704&type=smp

Which Leading Companies Are Shaping the Growth of the Acute Lung Injury Market?
Major companies operating in the acute lung injury market are Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Medtronic plc, Baxter International Inc., Ono Pharmaceutical Co Ltd., Aster DM Healthcare, Octapharma AG, Cartesian Therapeutics Inc., Vapotherm Inc., Stemedica Cell Technologies Inc., Implicit Bioscience Ltd., Apeiron Biologics AG, Faron Pharmaceuticals Ltd., Histocell Sociedad Limitada, Vasomune Therapeutics Inc, Windtree Therapeutics Inc., Qx Therapeutics Inc., Asklepion Pharmaceuticals LLC, ReAlta Life Sciences Inc., MediciNova Inc.

What Are the Major Trends Shaping the Acute Lung Injury Market?
Leading businesses in the acute lung injury market are concentrating on creating innovative treatments, including peptide treatments, in order to maintain their market dominance. Peptide treatment involves the use of amino acid short chains (peptides) as therapeutic agents for medical conditions. For example, in November 2022, Zuventus Healthcare Ltd., a healthcare company based in India, introduced Aviptadil to treat acute respiratory distress syndrome (ARDS). This treatment provides a range of unique advantages, including a potent vasodilatory property that is 50 times more effective than prostacyclin, a mechanism for lung protection that stimulates surfactant production by interacting with alveolar type II cells, anti-inflammatory effects that suppress pro-inflammatory cytokines such as IL-6 and TNF-alpha, and an immunomodulatory function to manage immune responses in the lungs. Clinically, Aviptadil has demonstrated efficacy in improving results for patients with severe virus-related ARDS.

What Are the Key Segments of the Acute Lung Injury Market?
The acute lung injury market covered in this report is segmented -

1) By Injury Type: Direct Injury, Indirect Injury
2) By Therapy: Mechanical Ventilation, Pharmacotherapy, Fluid Management, Other Therapies
3) By End User: Hospitals, Clinics, Other End Users

Subsegments:
1) By Direct Injury: Trauma-Induced Acute Lung Injury, Aspiration Pneumonitis, Pneumonia-Related Acute Lung Injury, Inhalation Injury
2) By Indirect Injury: Sepsis-Related Acute Lung Injury, Shock-Induced Acute Lung Injury, Acute Lung Injury Due To Blood Transfusion, Acute Lung Injury Associated With Pancreatitis

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/acute-lung-injury-global-market-report

Which Region Dominates the Acute Lung Injury Market?
North America was the largest region in the acute lung injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute lung injury market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Acute Lung Injury Global Market Report?

- Market Size Analysis: Analyze the acute lung injury Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the acute lung injury Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall acute lung injury market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the acute lung injury market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20704

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.